Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
ValiRx inks deal with Dundee Drug Discovery Unit
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday. The AIM-traded firm said the overarching agreement, set to span five years, would enable ValiRx to access research related to innovative therapeutic candidates.
Within the framework, ValiRx would have the opportunity to evaluate research projects from the DDU aligned with its strategic objectives, potentially leading to additional evaluation projects under pre-defined terms.
The inaugural evaluation agreement under the collaboration would be focussed on the exploration of a lead series of therapeutic candidates in the emerging field of pro-senescence.
ValiRx said pro-senescence involves selectively promoting ageing in cancer cells to halt their growth within tumours.
The research held promise for treating various cancer types as well as other disease areas linked to healthy ageing.
It said the initiative would build on pioneering research previously supported by Dundee and Barts Charity, led by Cleo Bishop, professor of senescence and director of the Queen Mary University London Phenotypic Screening Facility.
The evaluation process for the initial project was expected to last about 12 months, involving a comprehensive examination of the lead series for its mechanism of action and anti-cancer activity at the Inaphaea BioLabs facility, leveraging the expertise of external collaborators.
On completion of the evaluation, should the project meet the specified criteria, it would be considered for in-licensing based on pre-agreed terms.
"We are delighted to be able to streamline the process of reviewing and accessing the excellent research from University of Dundee's DDU, which will help to bring on evaluation projects more quickly," said chief executive officer Dr Suzy Dilly.
"The strength of the DDU and research facilities at Dundee are very impressive and, having reviewed multiple projects from teams there over the past year, we believe that this evaluation agreement will be the first of a series of new projects that can be brought into our pipeline."
At 1556 GMT, shares in ValiRx were up 1.06% at 4.75p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
